Understanding OUR Cytokine-Based Immunotherapy Candidates Our motivation extends to advancing a robust portfolio of programs geared toward expanding the horizons of cytokine-based immunotherapy, especially for cancers where treatment alternatives remain limited. Utilize the links below to learn additional about our portfolio of cytokine-based immunotherapy candidates. Take a look at https://financefeeds.com/4otc-appoints-kyle-jannece-as-head-of-business-development/